A randomized control trial on the safety and efficacy of ferric carboxymaltose versus ferumoxytol to treat iron deficiency showed that both of these intravenous iron preparations in the subgroup of patients with CKD reduced total FGF23 levels accompanied by improvements in hemoglobin and iron parameters. This evidence concerns the gene FGF23 and nutritional disorder.